# Immuneering Corp: overview

IMRX · Nasdaq · CIK 1790340 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imrx.md) · [Financials](/companies/imrx/financials.md) · [Filings](/companies/imrx/filings.md) · [Insiders](/companies/imrx/insiders.md)

Latest reported revenue: [$0](/filings/0001790340-24-000024.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 1, 2024 (XBRL us-gaap:Revenues, accession 0001790340-24-000024).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | not reported | [(0.42)](/filings/0001790340-26-000057.md) | [(0.40)](/filings/0001790340-26-000091.md) | [(0.38)](/filings/0001790340-26-000097.md) | not reported | [(0.21)](/filings/0001790340-26-000057.md) | [(0.27)](/filings/0001790340-26-000091.md) | [(0.37)](/filings/0001790340-26-000097.md) |
| Free cash flow | $m | [(14.5) d](/filings/0001790340-26-000042.md) | [(14.1)](/filings/0001790340-26-000057.md) | [(9.4) d](/filings/0001790340-26-000091.md) | [(12.0) d](/filings/0001790340-26-000097.md) | [(10.0) d](/filings/0001790340-26-000042.md) | [(18.5)](/filings/0001790340-26-000057.md) | [(16.5) d](/filings/0001790340-26-000091.md) | [(16.8) d](/filings/0001790340-26-000097.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.1](/filings/0001558370-23-002905.md) | [0.3](/filings/0001790340-24-000024.md) | [0.0](/filings/0001790340-24-000024.md) | not reported | not reported |
| Gross margin | % | [44.6%](/filings/0001558370-23-002905.md) | [50.1%](/filings/0001790340-24-000024.md) | not reported | not reported | not reported |
| Operating margin | % | [(1629.2%)](/filings/0001558370-23-002905.md) | [(16325.8%)](/filings/0001790340-24-000024.md) | not reported | not reported | not reported |
| Net margin | % | [(1612.3%)](/filings/0001558370-23-002905.md) | [(15937.3%)](/filings/0001790340-24-000024.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.46)](/filings/0001558370-23-002905.md) | [(1.91)](/filings/0001790340-24-000024.md) | [(1.88)](/filings/0001790340-25-000042.md) | [(2.04)](/filings/0001790340-26-000042.md) | [(1.27)](/filings/0001790340-26-000042.md) |
| Free cash flow | $m | [(30.9)](/filings/0001558370-23-002905.md) | [(44.8)](/filings/0001790340-24-000024.md) | [(49.3)](/filings/0001790340-25-000042.md) | [(55.1)](/filings/0001790340-26-000042.md) | [(45.5)](/filings/0001790340-26-000042.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imrx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $48.4m | 9,704,610 |  | Added +6,672 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.8m | 4,374,020 |  | Added +2,866,762 |
| [Sanofi](/funds/1121404.md) | 2026-06-30 | $13.5m | 2,708,559 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $11.4m | 2,286,434 |  | Reduced −1,907 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $6.8m | 1,370,750 |  | Added +732,806 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $5.0m | 1,001,995 |  | Added +733,475 |
| [DCF Advisers, LLC](/funds/1802493.md) | 2026-06-30 | $3.9m | 790,000 |  | Added +648,538 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.7m | 731,897 |  | Reduced −1,264,688 |
| [Connor, Clark & Lunn Investment Management Ltd.](/funds/1596800.md) | 2026-06-30 | $3.0m | 601,255 |  | Added +200,892 |
| [ALETHEA CAPITAL MANAGEMENT, LLC](/funds/1549408.md) | 2026-06-30 | $2.4m | 472,935 |  | Added +450,000 |

## Recent filings

[All 321 filings](/companies/imrx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:22 ET | [10-Q](/filings/0001790340-26-000097.md) | Quarterly report, period 2026-09-30 | 0001790340-26-000097 |
| 2026-10-29 | 16:12 ET | [8-K](/filings/0001790340-26-000095.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001790340-26-000095 |
| 2026-08-05 | 07:57 ET | [10-Q](/filings/0001790340-26-000091.md) | Quarterly report, period 2026-06-30 | 0001790340-26-000091 |
| 2026-08-05 | 07:41 ET | [8-K](/filings/0001790340-26-000088.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001790340-26-000088 |
| 2026-06-15 | 16:12 ET | [8-K](/filings/0001790340-26-000074.md) | 5.02 Departure or appointment of officers or directors | 0001790340-26-000074 |
| 2026-06-11 | 17:16 ET | [8-K](/filings/0001790340-26-000062.md) | 5.07 Shareholder vote results | 0001790340-26-000062 |
| 2026-06-01 | 16:51 ET | [8-K](/filings/0001790340-26-000059.md) | 8.01 Other events | 0001790340-26-000059 |
| 2026-05-15 | 07:52 ET | [10-Q](/filings/0001790340-26-000057.md) | Quarterly report, period 2026-03-31 | 0001790340-26-000057 |
| 2026-05-15 | 07:43 ET | [8-K](/filings/0001790340-26-000055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001790340-26-000055 |
| 2026-04-20 | 16:10 ET | [DEF 14A](/filings/0001790340-26-000048.md) | Proxy statement, period 2026-04-20 | 0001790340-26-000048 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001790340-26-000042.md), filed Mar 6, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1790340
- Tickers: IMRX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:24 ET. No prices; not investment advice.